The GLP-1 receptor agonist Exenatide reduces serum TSH by its effect on body weight in people with Type 2 Diabetes.

Exenatide therapy reduces serum TSH levels and improves central sensitivity to TH action over 12 months via its effect on weight loss. The effectiveness of weight loss strategies, rather than TH replacement, should be investigated in individuals with obesity and mildly raised serum TSH levels. This article is protected by copyright. All rights reserved.